NCT02079675View on ClinicalTrials.gov

Study to Assess the Efficacy and Safety of SKI3246 in Subjects With Non-Constipation Irritable Bowel Syndrome

PHASE2CompletedINTERVENTIONAL

Enrollment

279

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

April 30, 2014

Conditions

Non-constipation Irritable Bowel Syndrome

Interventions

DRUG

SKI3246 Low Dose

SKI3246 Low Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening

DRUG

SKI3246 High Dose

SKI3246 High Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening

DRUG

Placebo

SKI3246 Placebo will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening

Trial Locations (1)

Unknown

SK Chemicals, Seoul

All Listed Sponsors

lead

SK Chemicals Co., Ltd.

INDUSTRY

NCT02079675 - Study to Assess the Efficacy and Safety of SKI3246 in Subjects With Non-Constipation Irritable Bowel Syndrome | Biotech Hunter | Biotech Hunter